Abbott Healthcare announced that the Indian government has launched a probe into its supply chain after concerns over the misuse of its codeine‑based cough syrup, Phensedyl. The announcement came on January 23, 2026, following a plant inspection in Himachal Pradesh on January 14 and a seizure of 30,000 bottles in Ghaziabad in November 2025.
The investigation focuses on allegations that the quantity of Phensedyl sold in Uttar Pradesh far exceeded actual consumption, suggesting diversion for illicit use. Abbott said it cooperated fully with inspectors and has already halted production of Phensedyl as of December 2024 to address the diversion concerns.
The probe could lead to regulatory penalties, supply‑chain disruptions, and reputational damage for Abbott Laboratories, the parent company. Analysts note that the case highlights the company’s exposure to regulatory risk in emerging markets, where drug‑distribution controls are tightening.
Abbott’s Q4 2025 earnings, released on January 22, 2026, showed revenue of $11.46 billion, missing the consensus estimate of $11.78 billion by 2.76%. Adjusted EPS of $1.50 matched expectations, driven by strong performance in medical devices and diagnostics, offset by a decline in the nutrition segment. The company’s operating margin expanded to 25.8% from 24.1% in the prior year, reflecting cost‑control measures and a favorable product mix.
Management guidance for 2026 remains unchanged, with a midpoint organic sales growth of 7% and adjusted EPS growth of 10%. CEO Robert Ford emphasized that Abbott is committed to compliance and will continue to monitor distribution channels to prevent future diversion. The regulatory scrutiny, however, adds a headwind that could affect the company’s market perception and operational focus in India.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.